Intra-Cellular Therapies. has filed a patent for salts and crystal forms of a substituted heterocycle fused gamma-carboline. The patent claims a specific compound, d2-lumateperone, in various salt forms or co-crystals, which can be used in the treatment of diseases involving certain receptor signaling pathways. GlobalData’s report on Intra-Cellular Therapies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intra-Cellular Therapies, Peptide pharmacophores was a key innovation area identified from patents. Intra-Cellular Therapies's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a salt or crystal form of a substituted heterocycle fused gamma-carboline
A recently filed patent (Publication Number: US20230312573A1) describes a specific compound called d2-lumateperone and its various forms, including salts and co-crystals. The patent claims that these forms of d2-lumateperone are in solid crystalline form and can be used for the prophylaxis or treatment of diseases or abnormal conditions involving or mediated by the 5-HT2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways.
The patent claims that d2-lumateperone can exist in different forms, including salts and co-crystals. These forms are specified as hydrochloride, mono-tosylate, or bis-tosylate salts, as well as co-crystals with isonicotinamide or lysine free base. The patent emphasizes that these forms are in solid crystalline form.
The patent also describes the methods of making these salts and co-crystals. For salts, the method involves reacting the free base form of d2-lumateperone with hydrochloric acid or toluenesulfonic acid in the presence of an organic solvent. For co-crystals, the method involves combining the free base form of d2-lumateperone with isonicotinamide or combining d2-lumateperone mono-tosylate with lysine free base, again in the presence of an organic solvent.
Furthermore, the patent mentions a method of purifying d2-lumateperone in its free or salt form. This method involves reacting d2-lumateperone with hydrochloric acid or toluenesulfonic acid, or combining the free base form of d2-lumateperone with isonicotinamide or d2-lumateperone mono-tosylate with lysine free base. The resulting salt or co-crystal can then be optionally converted back to d2-lumateperone free base or another salt form.
The patent also highlights the potential therapeutic applications of these salts and co-crystals. It claims that administering an effective amount of these forms of d2-lumateperone can be used for the prophylaxis or treatment of diseases or abnormal conditions involving or mediated by the 5-HT2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways.
In addition, the patent mentions the possibility of formulating a pharmaceutical composition using these salts in combination with a pharmaceutically acceptable diluent or carrier.
Overall, this patent describes the various forms of d2-lumateperone, including salts and co-crystals, their methods of preparation, and their potential therapeutic applications in diseases or abnormal conditions involving specific receptor signaling pathways.
To know more about GlobalData’s detailed insights on Intra-Cellular Therapies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
